Clinical trials have demonstrated that PD1/PD-L1 inhibitors, like nivolumab, substantially enhance survival and response rates in advanced ccRCC patients, correlating closely with PD-L1 expression levels and tumor mutational burden. Here, CD274 is linked to neoplasm.